Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

3978 - Could a Systemic Inflammation Response Index (SIRI) predict Overall Survival (OS) in metastatic Pancreatic Cancer (PC)?


11 Sep 2017


Poster display session


Cancers in Adolescents and Young Adults (AYA);  Translational Research;  Pancreatic Cancer


Vilma Pacheco Barcia


Annals of Oncology (2017) 28 (suppl_5): v22-v42. 10.1093/annonc/mdx363


V. Pacheco Barcia, O. Donnay, R. Mondejar, J. Rogado, M.D. Fenor de la Maza, R. Colomer

Author affiliations

  • Medical Oncology, Hospital Universitario de La Princesa, 28006 - Madrid/ES


Abstract 3978


Cancer-associated inflammation is a key molecular feature of PC and may affect the clinical course. The aim of this study was to evaluate the prognostic relevance of SIRI based on peripheral neutrophil, monocyte, and lymphocyte counts in metastatic PC and its association with the metastatic site.


Retrospective analysis of the medical records of patients with pathologically confirmed metastatic PC between January 2011 and December 2016. Patients were classified as having liver metastases (LM) or extrahepatic metastases alone (EM). Associations with overall survival (OS) were analyzed using Cox proportional models.


A total of 37 patients were included (47 men; median age 63). Median TTP was 4 months and median OS was 6 months. 29 patients (78%) had LM and 8 (22%) EM. 33 patients (89%) received CT: 13 (40%) Gemcitabine (GEM) plus Nab-Paclitaxel, 9 (27%) GEM in monotherapy, 7 (21%) GEM plus Erlotinib and 4 (12%) an Oxaliplatine doublet. Mean Ca 19 9 levels in patients with LM were 199349 and with EM 9107. Univariate analysis identified SIRI scores ≥1,9 as significant risk factor for OS. Age, sex and high CA 19,9 levels had no prognostic significance for OS in all groups. Patients with LM showed a higher SIRI than those with EM (p = 0,03). Patients with SIRI scores < 1,9 (55%) compared to those who had SIRI scores ≥1,9 (45%) had a longer OS (p = 0,01). LM were significantly associated with shorter OS (hazard ratio [HR] 2.79; 95% confidence interval [CI] 1.36-5.34; p = 0,002) but not those with EM (HR 1.83; CI 0.71-4.72; p = 0,2). An SIRI ≥1,9 resulted in a shorter OS compared to an SIRI


SIRI is associated with survival in patients with metastatic PC. In patients with LM, unfavourable SIRI may be associated with higher tumor burden. In our experience, a baseline SIRI ≥1.9 duplicates the risk of mortality and this finding may allow better risk stratification.

Clinical trial identification

Legal entity responsible for the study

Medical Oncology Department, Hospital Universitario de La Princesa




All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.